Abbott Laboratories Faces Stock Decline Due to Guidance Revision and Regulatory Issues
Abbott Laboratories (ABT) has experienced a significant stock decline, dropping 26% over five months, driven by a revised earnings guidance and regulatory challenges with its FreeStyle Libre glucose monitor. The company's guidance was lowered due to the $21 billion Exact Sciences acquisition, while the FDA has issued a Class I recall and warning letter over manufacturing defects linked to the device.
Topics: acquisition impact earnings guidance FDA recall regulatory issues stock price decline